The safety, tolerability, and immunogenicity of the IDH1-vac vaccine in combination with the immune checkpoint inhibitor avelumab (AVE) in patients with IDH1R132H-mutant gliomas are being examined in the AMPLIFY-NEOVAC study (NCT03893903). This evidence concerns the gene IDH1 and glioma.